{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T05:09:26Z","timestamp":1747199366741,"version":"3.40.5"},"reference-count":27,"publisher":"Akademiai Kiado Zrt.","issue":"2","license":[{"start":{"date-parts":[[2022,6,20]],"date-time":"2022-06-20T00:00:00Z","timestamp":1655683200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["akjournals.com"],"crossmark-restriction":true},"short-container-title":["MaSeb"],"published-print":{"date-parts":[[2022,6,20]]},"abstract":"\n Bevezet\u00e9s<\/jats:title>\n Napjainkban az el\u0151rehaladott T2\u2013T4-st\u00e1dium\u00fa, ak\u00e1r regionalis nyirokcsom\u00f3 \u00e9rintetts\u00e9ggel b\u00edr\u00f3 gyomor-cardia tumoros betegek eset\u00e9ben a ter\u00e1pi\u00e1s algorytmus szerint neoadjuvans kezel\u00e9s t\u00f6rt\u00e9nik, majd azt k\u00f6veti a seb\u00e9szeti beavatkoz\u00e1s.<\/jats:p>\n <\/jats:sec>\n \n Betegek \u00e9s m\u00f3dszer<\/jats:title>\n A neoadjuvans onkol\u00f3giai kezel\u00e9s \u2212 a gastro-oesophagealis junctio tumorainak eset\u00e9ben \u2212 kor\u00e1bban az epirubicin, cisplatin \u00e9s fluorouracil (ECF) vagy epirubicin, cisplatin \u00e9s capecitabin (ECX) kombin\u00e1ciob\u00f3l \u00e1llt (I. csoport). Az \u00fajonnan alkalmazott ter\u00e1pi\u00e1s protokoll (FLOT-, F: 5-FU, L: leucovorin, O: oxaliplatin, T: docetaxel) vizsg\u00e1lat\u00e1ba a resecabilisnak \u00edt\u00e9lt cT2 vagy magasabb st\u00e1diumba soroland\u00f3 nyirokcsom\u00f3-pozit\u00edv betegeket cN+) v\u00e1logattuk be (II. csoport). Klinik\u00e1nkon 2013. december 31. \u00e9s 2021. j\u00fanius 1. k\u00f6z\u00f6tt FLOT-kezel\u00e9sen \u00e1tesett, T2\u2013T4-st\u00e1dium\u00fa cardiatumoros betegeink retrospectiv anal\u00edzis\u00e9t v\u00e9gezt\u00fck el (n<\/jats:italic> = 9). Az eredm\u00e9nyeket \u00f6sszehasonl\u00edtottuk a kor\u00e1bbi ECF\/ECX-kezel\u00e9sb\u0151l random m\u00f3don kiv\u00e1lasztott m\u00e1sik 9 beteg eredm\u00e9ny\u00e9vel. Kutat\u00e1sunk sor\u00e1n vizsg\u00e1ltuk az elt\u00e9r\u0151 kezel\u00e9si m\u00f3dszerek tumorregresszi\u00f3s v\u00e1ltoz\u00e1sait (TRG), lehets\u00e9ges mell\u00e9khat\u00e1s profiljait, az elv\u00e9gzett m\u0171t\u00e9tek t\u00edpusait, azok onkol\u00f3giai radikalit\u00e1s\u00e1t (nyirokcsom\u00f3sz\u00e1m, resecti\u00f3s sz\u00e9lek).<\/jats:p>\n <\/jats:sec>\n \n Eredm\u00e9nyek<\/jats:title>\n A k\u00e9t csoport eredm\u00e9nyeit \u00f6sszehasonl\u00edtva a FLOT neoadjuvans kezel\u00e9sen \u00e1tesett betegekn\u00e9l szignifik\u00e1nsan magasabb komplett pathol\u00f3giai regresszi\u00f3t \u00e9szlelt\u00fcnk, mint a \u2013 kor\u00e1bbi \u2013 ECX\/ECF-kezel\u00e9sekn\u00e9l. A m\u0171t\u00e9tek sor\u00e1n elt\u00e1vol\u00edtott nyirokcsom\u00f3k sz\u00e1m\u00e1ban, a seb\u00e9szi resecti\u00f3s sz\u00e9lek (distalis, circumferentialis) nagys\u00e1g\u00e1ban a csoportok k\u00f6z\u00f6tt szignifik\u00e1ns elt\u00e9r\u00e9s nem igazol\u00f3dott. A vizsg\u00e1latban a leggyakoribb mell\u00e9khat\u00e1sk\u00e9nt a neutropenia jelentkezett. A leukopenia, neutropenia, h\u00e1nyinger j\u00f3val gyakrabban jelent meg a kor\u00e1bban alkalmazott (ECF\/ECX) protokoll kapcs\u00e1n.<\/jats:p>\n <\/jats:sec>\n \n K\u00f6vetkeztet\u00e9s<\/jats:title>\n Az el\u0151rehaladott st\u00e1dium\u00fa gyomor-cardia tumorok eset\u00e9ben alkalmazott \u00faj FLOT neoadjuvans kezel\u00e9s szignifik\u00e1nsan magasabb m\u00e9rt\u00e9k\u0171 komplett pathol\u00f3giai tumorregresszi\u00f3t eredm\u00e9nyezett. Vizsg\u00e1lati eredm\u00e9nyeink alapj\u00e1n elmondhat\u00f3, hogy a kedvez\u0151bb mell\u00e9khat\u00e1s profillal rendelkez\u0151 FLOT neoadjuvans kezel\u00e9s, majd azt k\u00f6vet\u0151 seb\u00e9szeti beavatkoz\u00e1s a k\u00f6vetend\u0151 elj\u00e1r\u00e1s k\u00e9s\u0151i cardia tumorok eset\u00e9ben.<\/jats:p>\n <\/jats:sec>","DOI":"10.1556\/1046.2022.20008","type":"journal-article","created":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T15:51:08Z","timestamp":1655913068000},"page":"142-150","update-policy":"https:\/\/doi.org\/10.1556\/policypage.crossmark.crossref.2","source":"Crossref","is-referenced-by-count":0,"title":["A neoadjuvans FLOT-ter\u00e1pia hat\u00e1sa az el\u0151rehaladott gyomor-cardia tumorok r\u00f6vid t\u00e1v\u00fa onkol\u00f3giai \u00e9s seb\u00e9szi kezel\u00e9s eredm\u00e9nyeire"],"prefix":"10.1556","volume":"75","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1637-8652","authenticated-orcid":true,"given":"Attila","family":"Paszt","sequence":"first","affiliation":[{"name":"Szegedi Tudom\u00e1nyegyetem Szent-Gy\u00f6rgyi Albert Orvostudom\u00e1nyi Kar, Seb\u00e9szeti Klinika, Szeged, Magyarorsz\u00e1g (tansz\u00e9kvezet\u0151: Prof. Dr. L\u00e1z\u00e1r Gy\u00f6rgy)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zsolt","family":"Simonka","sequence":"additional","affiliation":[{"name":"Szegedi Tudom\u00e1nyegyetem Szent-Gy\u00f6rgyi Albert Orvostudom\u00e1nyi Kar, Seb\u00e9szeti Klinika, Szeged, Magyarorsz\u00e1g (tansz\u00e9kvezet\u0151: Prof. Dr. L\u00e1z\u00e1r Gy\u00f6rgy)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krisztina","family":"Budai","sequence":"additional","affiliation":[{"name":"Szegedi Tudom\u00e1nyegyetem Szent-Gy\u00f6rgyi Albert Orvostudom\u00e1nyi Kar, Seb\u00e9szeti Klinika, Szeged, Magyarorsz\u00e1g (tansz\u00e9kvezet\u0151: Prof. Dr. L\u00e1z\u00e1r Gy\u00f6rgy)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00e1rton","family":"Erd\u0151s","sequence":"additional","affiliation":[{"name":"Szegedi Tudom\u00e1nyegyetem Szent-Gy\u00f6rgyi Albert Orvostudom\u00e1nyi Kar, Seb\u00e9szeti Klinika, Szeged, Magyarorsz\u00e1g (tansz\u00e9kvezet\u0151: Prof. Dr. L\u00e1z\u00e1r Gy\u00f6rgy)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00e1rton","family":"Vas","sequence":"additional","affiliation":[{"name":"Szegedi Tudom\u00e1nyegyetem Szent-Gy\u00f6rgyi Albert Orvostudom\u00e1nyi Kar, Seb\u00e9szeti Klinika, Szeged, Magyarorsz\u00e1g (tansz\u00e9kvezet\u0151: Prof. Dr. L\u00e1z\u00e1r Gy\u00f6rgy)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aur\u00e9l","family":"Ottlak\u00e1n","sequence":"additional","affiliation":[{"name":"Szegedi Tudom\u00e1nyegyetem Szent-Gy\u00f6rgyi Albert Orvostudom\u00e1nyi Kar, Seb\u00e9szeti Klinika, Szeged, Magyarorsz\u00e1g (tansz\u00e9kvezet\u0151: Prof. Dr. L\u00e1z\u00e1r Gy\u00f6rgy)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zolt\u00e1n","family":"Szepes","sequence":"additional","affiliation":[{"name":"Szegedi Tudom\u00e1nyegyetem Szent-Gy\u00f6rgyi Albert Orvostudom\u00e1nyi Kar, Belgy\u00f3gy\u00e1szati Klinika, Szeged, Magyarorsz\u00e1g (tansz\u00e9kvezet\u0151: Prof. Dr. Lengyel Csaba)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L\u00e1szl\u00f3","family":"Torday","sequence":"additional","affiliation":[{"name":"Szegedi Tudom\u00e1nyegyetem Szent-Gy\u00f6rgyi Albert Orvostudom\u00e1nyi Kar, Onkoter\u00e1pi\u00e1s Klinika, Szeged, Magyarorsz\u00e1g (tansz\u00e9kvezet\u0151: Prof. Dr. Ol\u00e1h Judit)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L\u00e1szl\u00f3","family":"Tiszlavicz","sequence":"additional","affiliation":[{"name":"Szegedi Tudom\u00e1nyegyetem Szent-Gy\u00f6rgyi Albert Orvostudom\u00e1nyi Kar, Pathol\u00f3giai Int\u00e9zet, Szeged, Magyarorsz\u00e1g (tansz\u00e9kvezet\u0151: Prof. Dr. Tiszlavicz L\u00e1szl\u00f3)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gy\u00f6rgy","family":"L\u00e1z\u00e1r","sequence":"additional","affiliation":[{"name":"Szegedi Tudom\u00e1nyegyetem Szent-Gy\u00f6rgyi Albert Orvostudom\u00e1nyi Kar, Seb\u00e9szeti Klinika, Szeged, Magyarorsz\u00e1g (tansz\u00e9kvezet\u0151: Prof. Dr. L\u00e1z\u00e1r Gy\u00f6rgy)"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"425","reference":[{"key":"B1","series-title":"Semin Radiat Oncol","first-page":"3","article-title":"Epidemiology and risk factors for gastroesophageal junction tumors: understanding the rising incidence of this disease","volume":"23","author":"Matthew \n FB","year":"2013","unstructured":"Matthew \n FB\n , \n Thomas \n L\n , \n Vaughan\n \n . Epidemiology and risk factors for gastroesophageal junction tumors: understanding the rising incidence of this disease. Semin Radiat Oncol \n 2013; 23: 3\u20139."},{"key":"B2","series-title":"Magy Seb","first-page":"51","article-title":"A korai Barrett-carcinom\u00e1k seb\u00e9szi kezel\u00e9se Surgical treatment for early Barrett cancer","volume":"62","author":"Horv\u00e1th \n \u00d6P","year":"2009","unstructured":"Horv\u00e1th \n \u00d6P\n \n . A korai Barrett-carcinom\u00e1k seb\u00e9szi kezel\u00e9se Surgical treatment for early Barrett cancer. Magy Seb \n 2009; 62: 51\u20138."},{"key":"B3","series-title":"Chirurg","first-page":"25","article-title":"Cardia cancer: attempt at a therapeutically relevant classification","volume":"58","author":"Siewert \n JR","year":"1987","unstructured":"Siewert \n JR\n , \n H\u00f6lscher \n AH\n , \n Becker \n K\n , \n G\u00f6ssner \n W\n \n . Cardia cancer: attempt at a therapeutically relevant classification. Chirurg \n 1987; 58: 25\u201332."},{"key":"B4","series-title":"Br J Surg","first-page":"1457","article-title":"Classification of adenocarcinoma of the oesophagogastric junction","volume":"85","author":"Siewert \n JR","year":"1998","unstructured":"Siewert \n JR\n , \n Stein \n HJ\n \n . Classification of adenocarcinoma of the oesophagogastric junction. Br J Surg \n 1998; 85: 1457\u20139."},{"key":"B5","series-title":"Diseases of the Esophagus","first-page":"173","article-title":"Carcinoma of the gastroesophageal junction \u2013 classification, pathology and extent of resection","volume":"9","author":"Siewert \n JR","year":"1996","unstructured":"Siewert \n JR\n , \n Stein \n HJ\n \n . Carcinoma of the gastroesophageal junction \u2013 classification, pathology and extent of resection. Diseases of the Esophagus \n 1996; 9: 173\u201382."},{"key":"B6","series-title":"J Natl Compr Canc Netw","first-page":"855","article-title":"Esophageal and esophagogastric junction cancers, version 2.2019. NCCN clinical practice guidelines in oncology","volume":"17","author":"Ajani \n JA","year":"2019","unstructured":"Ajani \n JA\n , \n D'Amico \n TA\n , \n Bentrem \n DJ\n , \n Chao \n J\n , \n Corvera \n C\n , \n Das \n P\n , et\u00a0al.\n \n Esophageal and esophagogastric junction cancers, version 2.2019. NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw \n 2019; 17: 855\u201383."},{"key":"B7","series-title":"Front Oncol","first-page":"567529","article-title":"Feasibility and safety of perioperative chemotherapy with fluorouracil plus Leucovorin, Oxaliplatin, and Docetaxel for locally advanced gastric cancer patients in China","volume":"10","author":"Sah \n BK","year":"2021","unstructured":"Sah \n BK\n , \n Xu \n W\n , \n Zhang \n B\n , \n Zhang \n H\n , \n Yuan \n F\n , \n Li \n J\n , et\u00a0al.\n \n Feasibility and safety of perioperative chemotherapy with fluorouracil plus Leucovorin, Oxaliplatin, and Docetaxel for locally advanced gastric cancer patients in China. Front Oncol \n 2021; 10: 567529."},{"key":"B8","series-title":"Med Oncol","first-page":"62","article-title":"A pilot trial of FLOT neoadjuvant chemotherapy for resectable esophagogastric junction adenocarcinoma","volume":"33","author":"Al-Fakeeh \n A","year":"2016","unstructured":"Al-Fakeeh \n A\n , \n Ferri \n L\n , \n Mulla \n N\n , \n Doerksen \n T\n , \n Al-Ruzug \n I\n , \n Santos \n F\n , et\u00a0al.\n \n A pilot trial of FLOT neoadjuvant chemotherapy for resectable esophagogastric junction adenocarcinoma. Med Oncol \n 2016; 33: 62."},{"key":"B9","series-title":"J Clin Oncol","first-page":"1715","article-title":"Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial","volume":"29","author":"Ychou \n M","year":"2011","unstructured":"Ychou \n M\n , \n Boige \n V\n , \n Pignon \n JP\n , \n Conroy \n T\n , \n Bouch\u00e9 \n O\n , \n Lebreton \n G\n , et\u00a0al.\n \n Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol \n 2011; 29: 1715\u201321."},{"key":"B10","series-title":"N Engl J Med","first-page":"2074","article-title":"Preoperative chemoradiotherapy for esophageal or junctional cancer","volume":"366","author":"Van Hagen \n P","year":"2012","unstructured":"Van Hagen \n P\n , \n Hulshof \n MCCM\n , \n van Lanschot \n JJB\n , \n Steyerberg \n EW\n , \n van Berge Henegouwen \n MI\n , \n Wijnhoven \n BPL\n , et\u00a0al.\n \n Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med \n 2012; 366: 2074\u201384."},{"key":"B11","series-title":"Sci Rep","first-page":"15806","article-title":"Systematic review and meta-analysis of docetaxel perioperative chemotherapy regimens in gastric and esophagogastric tumors","volume":"9","author":"Uson Junior \n PLS","year":"2019","unstructured":"Uson Junior \n PLS\n , \n Santos \n VM\n , \n Bugano \n DDG\n , \n Victor \n EDS\n , \n Rother \n ET\n , \n Maluf \n FC\n \n . Systematic review and meta-analysis of docetaxel perioperative chemotherapy regimens in gastric and esophagogastric tumors. Sci Rep \n 2019; 9: 15806."},{"key":"B12","series-title":"Curr Opin Oncol","first-page":"347","article-title":"Multimodality treatment for localized gastric cancer: state of the art and new insights","volume":"32","author":"Petrillo \n A","year":"2020","unstructured":"Petrillo \n A\n , \n Smyth \n EC\n \n . Multimodality treatment for localized gastric cancer: state of the art and new insights. Curr Opin Oncol \n 2020; 32: 347\u201355."},{"key":"B13","series-title":"Curr Treat Options Oncol","first-page":"57","article-title":"Optimizing therapies in the perioperative management of gastric cancer","volume":"20","author":"Khan \n U","year":"2019","unstructured":"Khan \n U\n , \n Shah \n MA\n \n . Optimizing therapies in the perioperative management of gastric cancer. Curr Treat Options Oncol \n 2019; 20: 57."},{"key":"B14","series-title":"N Engl J Med","first-page":"11","article-title":"Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer","volume":"355","author":"Cunningham \n D","year":"2006","unstructured":"Cunningham \n D\n , \n Allum \n WH\n , \n Stenning \n SP\n , \n Thompson \n JN\n , \n van de Velde \n CJH\n , \n Nicolson \n M\n , et\u00a0al.\n \n Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med \n 2006; 355: 11\u201320."},{"key":"B15","series-title":"Surg Today","first-page":"809","article-title":"True esophagogastric junction adenocarcinoma: background of its definition and current surgical trends","volume":"50","author":"Kumamoto \n T","year":"2020","unstructured":"Kumamoto \n T\n , \n Kurahashi \n Y\n , \n Niwa \n H\n , \n Nakanishi \n Y\n , \n Okumara \n K\n , \n Ozawa \n R\n , et\u00a0al.\n \n True esophagogastric junction adenocarcinoma: background of its definition and current surgical trends. Surg Today \n 2020; 50: 809\u201314."},{"key":"B16","series-title":"Ann N Y Acad Sci","first-page":"77","article-title":"Current surgical treatment standards for esophageal and esophagogastric junction cancer","volume":"1482","author":"Jung \n MK","year":"2020","unstructured":"Jung \n MK\n , \n Schmidt \n T\n , \n Chon \n SH\n , \n Chevallay \n M\n , \n Berlth \n F\n , \n Akiyama \n J\n , et\u00a0al.\n \n Current surgical treatment standards for esophageal and esophagogastric junction cancer. Ann N Y Acad Sci \n 2020; 1482: 77\u201384."},{"key":"B17","series-title":"J Gastrointest Surg","first-page":"58","article-title":"Operative results and perioperative morbidity after intensified neoadjuvant chemotherapy with FLOT for gastroesophageal adenocarcinoma impact of intensified neoadjuvant treatment","volume":"25","author":"Ganschow \n P","year":"2021","unstructured":"Ganschow \n P\n , \n Hofmann \n L\n , \n Stintzing \n S\n , \n Heinemann \n V\n , \n Angele \n M\n , \n Werner \n J\n , et\u00a0al.\n \n Operative results and perioperative morbidity after intensified neoadjuvant chemotherapy with FLOT for gastroesophageal adenocarcinoma impact of intensified neoadjuvant treatment. J Gastrointest Surg \n 2021; 25: 58\u201366."},{"key":"B18","series-title":"Eur J Surg Oncol","first-page":"2473","article-title":"Adenocarcinoma of the oesophagogastric junction Siewert II: an oesophageal cancer better cured with total gastrectomy","volume":"45","author":"Voron \n T","year":"2019","unstructured":"Voron \n T\n , \n Gronnier \n C\n , \n Pasquer \n A\n , \n Thereaux \n J\n , \n Gagniere \n J\n , \n Lebreton \n G\n , et\u00a0al.\n \n Adenocarcinoma of the oesophagogastric junction Siewert II: an oesophageal cancer better cured with total gastrectomy. Eur J Surg Oncol \n 2019; 45: 2473\u201381."},{"key":"B19","series-title":"BMC Cancer","first-page":"781","article-title":"The CARDIA-trial protocol: a multinational, prospective, randomized, clinical trial comparing transthoracic esophagectomy with transhiatal extended gastrectomy in adenocarcinoma of the gastroesophageal junction (GEJ) type II","volume":"20","author":"Leers \n JM","year":"2020","unstructured":"Leers \n JM\n , \n Knepper \n L\n , \n van der Veen \n A\n , \n Schr\u00f6der \n W\n , \n Fuchs \n H\n , \n Schiller \n P\n , et\u00a0al.\n \n The CARDIA-trial protocol: a multinational, prospective, randomized, clinical trial comparing transthoracic esophagectomy with transhiatal extended gastrectomy in adenocarcinoma of the gastroesophageal junction (GEJ) type II. BMC Cancer \n 2020; 20: 781."},{"key":"B20","series-title":"Gastric Cancer","first-page":"3","article-title":"Esophagogastric junction adenocarcinomas: individualization of resection with special considerations for Siewert type II, and Nishi types EG, E=G and GE cancers","volume":"23","author":"H\u00f6lscher \n AH","year":"2020","unstructured":"H\u00f6lscher \n AH\n , \n Law \n S\n \n . Esophagogastric junction adenocarcinomas: individualization of resection with special considerations for Siewert type II, and Nishi types EG, E=G and GE cancers. Gastric Cancer \n 2020; 23: 3\u20139."},{"key":"B21","series-title":"Gastric Cancer","first-page":"312","article-title":"Long-term quality of life after surgery for adenocarcinoma of the esophagogastric junction: extended gastrectomy or transthoracic esophagectomy?","volume":"19","author":"Fuchs \n H","year":"2016","unstructured":"Fuchs \n H\n , \n H\u00f6lscher \n AH\n , \n Leers \n J\n , \n Bludau \n M\n , \n Brinkmann \n S\n , \n Schr\u00f6der \n W\n , et\u00a0al.\n \n Long-term quality of life after surgery for adenocarcinoma of the esophagogastric junction: extended gastrectomy or transthoracic esophagectomy? \n Gastric Cancer \n 2016; 19: 312\u20137."},{"key":"B22","series-title":"Br J Surg","first-page":"1547","article-title":"Effects of hybrid minimally invasive oesophagectomy on major postoperative pulmonary complications","volume":"99","author":"Briez \n N","year":"2012","unstructured":"Briez \n N\n , \n Piessen \n G\n , \n Torres \n F\n , \n Lebuffe \n G\n , \n Triboulet \n J-P\n , \n Mariette \n C\n \n . Effects of hybrid minimally invasive oesophagectomy on major postoperative pulmonary complications. Br J Surg \n 2012; 99: 1547\u201353."},{"key":"B23","series-title":"Surg Endosc","first-page":"4957","article-title":"Total minimally invasive esophagectomy for esophageal adenocarcinoma reduces postoperative pain and pneumonia compared to hybrid esophagectomy","volume":"32","author":"Berlth \n F","year":"2018","unstructured":"Berlth \n F\n , \n Plum \n PS\n , \n Chon \n SH\n , \n Gutschow \n CA\n , \n Bollschweiler\n , \n H\u00f6lscher \n AH\n \n . Total minimally invasive esophagectomy for esophageal adenocarcinoma reduces postoperative pain and pneumonia compared to hybrid esophagectomy. Surg Endosc \n 2018; 32: 4957\u201365."},{"key":"B24","series-title":"Surgery","first-page":"1073","article-title":"Early outcome of thoracoscopic and hybrid esophagectomy: propensity-matched comparative analysis","volume":"159","author":"Bonavina \n L","year":"2016","unstructured":"Bonavina \n L\n , \n Scolari \n F\n , \n Aiolfi \n A\n , \n Bonitta \n G\n , \n Sironi \n A\n , \n Saino \n G\n , et\u00a0al.\n \n Early outcome of thoracoscopic and hybrid esophagectomy: propensity-matched comparative analysis. Surgery \n 2016; 159: 1073\u201381."},{"key":"B25","series-title":"Ann Surg","first-page":"814","article-title":"Defining benchmarks for transthoracic esophagectomy: a multicenter analysis of total minimally invasive esophagectomy in low risk patients","volume":"266","author":"Schmidt \n HM","year":"2017","unstructured":"Schmidt \n HM\n , \n Gisbertz \n SS\n , \n Moons \n J\n , \n Rouvelas \n I\n , \n Kauppi \n J\n , \n Brown \n A\n , et\u00a0al.\n \n Defining benchmarks for transthoracic esophagectomy: a multicenter analysis of total minimally invasive esophagectomy in low risk patients. Ann Surg \n 2017; 266: 814\u201321."},{"key":"B26","series-title":"Ann Surg","first-page":"353","article-title":"Adenocarcinoma of the esophagogastric junction: results of surgical therapy based on anatomical\/topographic classification in 1,002 consecutive patients","volume":"232","author":"R\u00fcdiger Siewert \n J","year":"2000","unstructured":"R\u00fcdiger Siewert \n J\n , \n Feith \n M\n , \n Werner \n M\n , \n Stein \n HJ\n \n . Adenocarcinoma of the esophagogastric junction: results of surgical therapy based on anatomical\/topographic classification in 1,002 consecutive patients. Ann Surg \n 2000; 232: 353\u201361."},{"key":"B27","series-title":"Ann Surg","first-page":"962","article-title":"Three-field lymphadenectomy for carcinoma of the esophagus and gastroesophageal junction in 174 R0 resections: impact on staging, disease-free survival, and outcome: a plea for adaptation of TNM classification in upper-half esophageal carcinoma","volume":"240","author":"Lerut \n T","year":"2004","unstructured":"Lerut \n T\n , \n Nafteux \n P\n , \n Moons \n J\n , \n Coosemans \n W\n , \n Decker \n G\n , \n De Leyn \n P\n , et\u00a0al.\n \n Three-field lymphadenectomy for carcinoma of the esophagus and gastroesophageal junction in 174 R0 resections: impact on staging, disease-free survival, and outcome: a plea for adaptation of TNM classification in upper-half esophageal carcinoma. Ann Surg \n 2004; 240: 962\u201372."}],"container-title":["Magyar Seb\u00e9szet"],"original-title":[],"link":[{"URL":"https:\/\/akjournals.com\/view\/journals\/1046\/75\/2\/article-p142.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/akjournals.com\/downloadpdf\/journals\/1046\/75\/2\/article-p142.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/akjournals.com\/downloadpdf\/journals\/1046\/75\/2\/article-p142.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,21]],"date-time":"2023-02-21T10:28:22Z","timestamp":1676975302000},"score":1,"resource":{"primary":{"URL":"https:\/\/akjournals.com\/view\/journals\/1046\/75\/2\/article-p142.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,20]]},"references-count":27,"journal-issue":{"issue":"2"},"URL":"https:\/\/doi.org\/10.1556\/1046.2022.20008","relation":{},"ISSN":["0025-0295","1789-4301"],"issn-type":[{"type":"print","value":"0025-0295"},{"type":"electronic","value":"1789-4301"}],"subject":[],"published":{"date-parts":[[2022,6,20]]}}}